The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Intravenous (IV) Iron Drugs-Global Market Insights and Sales Trends 2025
Synopsis
The global Intravenous (IV) Iron Drugs market size is expected to reach US$ 172.4 million by 2029, growing at a CAGR of 7.8% from 2023 to 2029. The market is mainly driven by the significant applications of Intravenous (IV) Iron Drugs in various end use industries. The expanding demands from the Nephrology, Gynecology & Obstetrics, Gastroenterology and Oncology, are propelling Intravenous (IV) Iron Drugs market. Ferric Carboxymaltose, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Iron Sucrose segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Intravenous (IV) Iron Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Intravenous (IV) Iron Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Intravenous (IV) Iron Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Intravenous (IV) Iron Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Intravenous (IV) Iron Drugs covered in this report include Sanofi US, Allergan, AMAG Pharmaceuticals, Dalichi Sankyo, Luitpold Pharmaceuticals, Pharmacosmos and Takeda Pharmaceutical, etc.
The global Intravenous (IV) Iron Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sanofi US
Allergan
AMAG Pharmaceuticals
Dalichi Sankyo
Luitpold Pharmaceuticals
Pharmacosmos
Takeda Pharmaceutical
Global Intravenous (IV) Iron Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Intravenous (IV) Iron Drugs market, Segment by Type:
Ferric Carboxymaltose
Iron Sucrose
Iron Dextran
Others
Global Intravenous (IV) Iron Drugs market, by Application
Nephrology
Gynecology & Obstetrics
Gastroenterology
Oncology
Cardiology
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Intravenous (IV) Iron Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Intravenous (IV) Iron Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
The global Intravenous (IV) Iron Drugs market size is expected to reach US$ 172.4 million by 2029, growing at a CAGR of 7.8% from 2023 to 2029. The market is mainly driven by the significant applications of Intravenous (IV) Iron Drugs in various end use industries. The expanding demands from the Nephrology, Gynecology & Obstetrics, Gastroenterology and Oncology, are propelling Intravenous (IV) Iron Drugs market. Ferric Carboxymaltose, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Iron Sucrose segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Intravenous (IV) Iron Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Intravenous (IV) Iron Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Intravenous (IV) Iron Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Intravenous (IV) Iron Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Intravenous (IV) Iron Drugs covered in this report include Sanofi US, Allergan, AMAG Pharmaceuticals, Dalichi Sankyo, Luitpold Pharmaceuticals, Pharmacosmos and Takeda Pharmaceutical, etc.
The global Intravenous (IV) Iron Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sanofi US
Allergan
AMAG Pharmaceuticals
Dalichi Sankyo
Luitpold Pharmaceuticals
Pharmacosmos
Takeda Pharmaceutical
Global Intravenous (IV) Iron Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Intravenous (IV) Iron Drugs market, Segment by Type:
Ferric Carboxymaltose
Iron Sucrose
Iron Dextran
Others
Global Intravenous (IV) Iron Drugs market, by Application
Nephrology
Gynecology & Obstetrics
Gastroenterology
Oncology
Cardiology
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Intravenous (IV) Iron Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Intravenous (IV) Iron Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Intravenous (IV) Iron Drugs Market Overview
1.1 Intravenous (IV) Iron Drugs Product Overview
1.2 Intravenous (IV) Iron Drugs Market Segment by Type
1.2.1 Ferric Carboxymaltose
1.2.2 Iron Sucrose
1.2.3 Iron Dextran
1.2.4 Others
1.3 Global Intravenous (IV) Iron Drugs Market Size by Type
1.3.1 Global Intravenous (IV) Iron Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Intravenous (IV) Iron Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Intravenous (IV) Iron Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Intravenous (IV) Iron Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Intravenous (IV) Iron Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Intravenous (IV) Iron Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Intravenous (IV) Iron Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Intravenous (IV) Iron Drugs Sales Breakdown by Type (2018-2023)
2 Global Intravenous (IV) Iron Drugs Market Competition by Company
2.1 Global Top Players by Intravenous (IV) Iron Drugs Sales (2018-2023)
2.2 Global Top Players by Intravenous (IV) Iron Drugs Revenue (2018-2023)
2.3 Global Top Players by Intravenous (IV) Iron Drugs Price (2018-2023)
2.4 Global Top Manufacturers Intravenous (IV) Iron Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Intravenous (IV) Iron Drugs Market Competitive Situation and Trends
2.5.1 Intravenous (IV) Iron Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Intravenous (IV) Iron Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Intravenous (IV) Iron Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Intravenous (IV) Iron Drugs Market
2.8 Key Manufacturers Intravenous (IV) Iron Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Intravenous (IV) Iron Drugs Status and Outlook by Region
3.1 Global Intravenous (IV) Iron Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Intravenous (IV) Iron Drugs Historic Market Size by Region
3.2.1 Global Intravenous (IV) Iron Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Intravenous (IV) Iron Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Intravenous (IV) Iron Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Intravenous (IV) Iron Drugs Forecasted Market Size by Region
3.3.1 Global Intravenous (IV) Iron Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Intravenous (IV) Iron Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Intravenous (IV) Iron Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Intravenous (IV) Iron Drugs by Application
4.1 Intravenous (IV) Iron Drugs Market Segment by Application
4.1.1 Nephrology
4.1.2 Gynecology & Obstetrics
4.1.3 Gastroenterology
4.1.4 Oncology
4.1.5 Cardiology
4.1.6 Others
4.2 Global Intravenous (IV) Iron Drugs Market Size by Application
4.2.1 Global Intravenous (IV) Iron Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Intravenous (IV) Iron Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Intravenous (IV) Iron Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Intravenous (IV) Iron Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Intravenous (IV) Iron Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Intravenous (IV) Iron Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Intravenous (IV) Iron Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Intravenous (IV) Iron Drugs Sales Breakdown by Application (2018-2023)
5 North America Intravenous (IV) Iron Drugs by Country
5.1 North America Intravenous (IV) Iron Drugs Historic Market Size by Country
5.1.1 North America Intravenous (IV) Iron Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Intravenous (IV) Iron Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Intravenous (IV) Iron Drugs Sales in Value by Country (2018-2023)
5.2 North America Intravenous (IV) Iron Drugs Forecasted Market Size by Country
5.2.1 North America Intravenous (IV) Iron Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Intravenous (IV) Iron Drugs Sales in Value by Country (2024-2029)
6 Europe Intravenous (IV) Iron Drugs by Country
6.1 Europe Intravenous (IV) Iron Drugs Historic Market Size by Country
6.1.1 Europe Intravenous (IV) Iron Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Intravenous (IV) Iron Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Intravenous (IV) Iron Drugs Sales in Value by Country (2018-2023)
6.2 Europe Intravenous (IV) Iron Drugs Forecasted Market Size by Country
6.2.1 Europe Intravenous (IV) Iron Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Intravenous (IV) Iron Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Intravenous (IV) Iron Drugs by Region
7.1 Asia-Pacific Intravenous (IV) Iron Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Intravenous (IV) Iron Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Intravenous (IV) Iron Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Intravenous (IV) Iron Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Intravenous (IV) Iron Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Intravenous (IV) Iron Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Intravenous (IV) Iron Drugs Sales in Value by Region (2024-2029)
8 Latin America Intravenous (IV) Iron Drugs by Country
8.1 Latin America Intravenous (IV) Iron Drugs Historic Market Size by Country
8.1.1 Latin America Intravenous (IV) Iron Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Intravenous (IV) Iron Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Intravenous (IV) Iron Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Intravenous (IV) Iron Drugs Forecasted Market Size by Country
8.2.1 Latin America Intravenous (IV) Iron Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Intravenous (IV) Iron Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Intravenous (IV) Iron Drugs by Country
9.1 Middle East and Africa Intravenous (IV) Iron Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Intravenous (IV) Iron Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Intravenous (IV) Iron Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Intravenous (IV) Iron Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Intravenous (IV) Iron Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Intravenous (IV) Iron Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Intravenous (IV) Iron Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Sanofi US
10.1.1 Sanofi US Company Information
10.1.2 Sanofi US Introduction and Business Overview
10.1.3 Sanofi US Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Sanofi US Intravenous (IV) Iron Drugs Products Offered
10.1.5 Sanofi US Recent Development
10.2 Allergan
10.2.1 Allergan Company Information
10.2.2 Allergan Introduction and Business Overview
10.2.3 Allergan Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Allergan Intravenous (IV) Iron Drugs Products Offered
10.2.5 Allergan Recent Development
10.3 AMAG Pharmaceuticals
10.3.1 AMAG Pharmaceuticals Company Information
10.3.2 AMAG Pharmaceuticals Introduction and Business Overview
10.3.3 AMAG Pharmaceuticals Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 AMAG Pharmaceuticals Intravenous (IV) Iron Drugs Products Offered
10.3.5 AMAG Pharmaceuticals Recent Development
10.4 Dalichi Sankyo
10.4.1 Dalichi Sankyo Company Information
10.4.2 Dalichi Sankyo Introduction and Business Overview
10.4.3 Dalichi Sankyo Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Dalichi Sankyo Intravenous (IV) Iron Drugs Products Offered
10.4.5 Dalichi Sankyo Recent Development
10.5 Luitpold Pharmaceuticals
10.5.1 Luitpold Pharmaceuticals Company Information
10.5.2 Luitpold Pharmaceuticals Introduction and Business Overview
10.5.3 Luitpold Pharmaceuticals Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Luitpold Pharmaceuticals Intravenous (IV) Iron Drugs Products Offered
10.5.5 Luitpold Pharmaceuticals Recent Development
10.6 Pharmacosmos
10.6.1 Pharmacosmos Company Information
10.6.2 Pharmacosmos Introduction and Business Overview
10.6.3 Pharmacosmos Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Pharmacosmos Intravenous (IV) Iron Drugs Products Offered
10.6.5 Pharmacosmos Recent Development
10.7 Takeda Pharmaceutical
10.7.1 Takeda Pharmaceutical Company Information
10.7.2 Takeda Pharmaceutical Introduction and Business Overview
10.7.3 Takeda Pharmaceutical Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Takeda Pharmaceutical Intravenous (IV) Iron Drugs Products Offered
10.7.5 Takeda Pharmaceutical Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Intravenous (IV) Iron Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Intravenous (IV) Iron Drugs Industrial Chain Analysis
11.4 Intravenous (IV) Iron Drugs Market Dynamics
11.4.1 Intravenous (IV) Iron Drugs Industry Trends
11.4.2 Intravenous (IV) Iron Drugs Market Drivers
11.4.3 Intravenous (IV) Iron Drugs Market Challenges
11.4.4 Intravenous (IV) Iron Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Intravenous (IV) Iron Drugs Distributors
12.3 Intravenous (IV) Iron Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
